ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
P/E ratio for ANI Pharmaceuticals, Inc. (ANIP)
P/E ratio as of 2023: 52.86
According to ANI Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 52.86. At the end of 2022 the company had a P/E ratio of -13.66.
P/E ratio history for ANI Pharmaceuticals, Inc. from 1998 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 52.86 |
| 2022 | -13.66 |
| 2021 | -13.62 |
| 2020 | -15.41 |
| 2019 | 119.83 |
| 2018 | 33.93 |
| 2017 | -691.64 |
| 2016 | 176.36 |
| 2015 | 33.37 |
| 2014 | 21.46 |
| 2013 | 338.29 |
| 2012 | -0.97 |
| 2011 | -0.95 |
| 2010 | -2.34 |
| 2009 | -1.04 |
| 2008 | -1.57 |
| 2007 | -12.70 |
| 2006 | 21.03 |
| 2005 | -7.33 |
| 2004 | -7.82 |
| 2003 | -7.67 |
| 2002 | -6.60 |
| 2001 | -21.11 |
| 2000 | -12.55 |
| 1999 | -20.87 |
| 1998 | -7.78 |